

OBSTETRICS

Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting

Elena Sczzocchio, MD; Francesc Figueras, PhD; Fatima Crispi, PhD; Eva Meler, MD; Narcís Masoller, MD; Raquel Mula, MD; Eduard Gratacos, PhD

OBJECTIVE: We sought to evaluate the effectiveness of an integrated first-trimester screening test to predict preeclampsia (PE).

STUDY DESIGN: A prospective cohort of singleton pregnancies underwent routine first-trimester screening from 2009 through 2011 ($n = 5759$). A logistic regression-based predictive model for early- and late-onset PE was constructed based on: maternal characteristics; levels of pregnancy-associated plasma protein-A and free β -human chorionic gonadotropin at 8-12 weeks; and blood pressure and uterine artery Doppler at 11.0-13.6 weeks.

RESULTS: Of the 5170 enrolled participants, 136 (2.6%) developed PE (early PE: 26 [0.5%]; late PE: 110 [2.1%]). At 5% and 10% false-positive

rates, detection rates were 69.2% and 80.8% for early PE (area under the curve, 0.95; 95% confidence interval, 0.94–0.98) and 29.4% and 39.6% for late PE (area under the curve, 0.71; 95% confidence interval, 0.66–0.76), respectively.

CONCLUSION: First-trimester screening combining maternal factors with uterine artery Doppler, blood pressure, and pregnancy-associated plasma protein-A is useful to predict PE in a routine care setting.

Key words: blood pressure, preeclampsia, screening, uterine artery Doppler

Cite this article as: Sczzocchio E, Figueras F, Crispi F, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. *Am J Obstet Gynecol* 2013;208:203.e1-10.

Preeclampsia (PE) occurs in approximately 2-8% of pregnancies.¹ In developed countries, PE is the primary cause of maternal admission to intensive care units² and causes approximately 15% of all pregnancy-related deaths.³ Additionally, PE is associated with an increased risk of perinatal mortality and is

the cause for approximately 10% of stillbirths⁴ and 15% of preterm births.⁵

In recent years, the results of several studies indicate that a combination of maternal history, biochemical markers, and biophysical markers effectively predicts PE in the first trimester of pregnancy,⁶ a period in which prophylactic strategies with aspirin have been demonstrated to be more effective.⁷ The performance in the prediction of early-onset PE, which is the clinical form that contributes most significantly to adverse outcomes,⁸ is substantially higher than that for late forms of the disease. Thus detection rates (DR) for early PE ranged from 41% when using combinations of maternal history with pregnancy-associated plasma protein-A (PAPP-A),⁹ to 96%, when maternal factors, uterine artery (UtA) Doppler, and angiogenic factors were combined.¹⁰ In contrast, the DR for late PE ranges around 31–45%.^{9,11}

One gap in the current literature on the prediction of PE is that most studies have been performed in Anglo-Saxon populations and have been carried on under similar research settings.^{9,11-16}

Another study carried out on a Mediterranean population, with smaller sample size, did not differentiate early and late PE.¹⁷ Thus there is a need to confirm the effectiveness of first-trimester screening for PE when applied under typical clinical conditions and to populations different from those of the original studies.⁶ The composition of the population under study may strongly influence maternal a priori risk. For instance, in south-European countries the proportion of black race and the rates of obesity and chronic hypertension are lower than in the United Kingdom.¹⁸

In this study, we evaluated the effectiveness of an integrated first-trimester screening test for PE when performed under usual care conditions and in a south-European population. The screening strategy combined maternal history, blood pressure (BP), UtA Doppler, and biochemical markers (free β -human chorionic gonadotropin [β -HCG] and PAPP-A). The testing was conducted for 3 years in a clinical setting during routine first-trimester ultrasound and was performed by usual clinical staff. We evaluated the DR for early and late PE in 5759 patients.

From the Department of Maternal-Fetal Medicine, Institute Clinic of Gynecology, Obstetrics, and Neonatology, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, and Centre for Biomedical Research on Rare Diseases (CIBER-ER) (all authors), and the Department of Obstetrics, Gynecology, and Reproductive Medicine, Institut Universitari Dexeus (Drs Sczzocchio and Meler), Barcelona, Spain.

Received May 17, 2012; revised Dec. 5, 2012; accepted Dec. 7, 2012.

This study was sponsored by Siemens Healthcare Diagnostics, Tarrytown, NY.

Reprints: Francesc Figueras, PhD, Department of Maternal-Fetal Medicine, Hospital Clinic, University of Barcelona, Sabino de Arana 1, 08028 Barcelona, Spain. ffiguera@clinic.ub.es.

0002-9378/\$36.00

© 2013 Mosby, Inc. All rights reserved.

<http://dx.doi.org/10.1016/j.ajog.2012.12.016>

TABLE 1

Epidemiological and clinical characteristics of study population according to study groups

Variable	Unaffected (n = 5034)	Late PE (n = 110)	Early PE (n = 26)
Age, y, median (IQR)	32 (28–35.4)	33.2 (29–36.3)	31.3 (29.9–36.5)
BMI, kg/m ² , median (IQR)	24 (22.7–24.7)	24.6 (23.5–26.4) ^a	24.4 (22.7–28)
Ethnicity, n (%)			
White European	3757 (74.6)	73 (66.4)	15 (57.7)
Black	22 (0.4)	1 (0.9)	1 (3.8)
South American	784 (15.6)	28 (25.5)	6 (23.1)
Other	471 (9.4)	8 (7.3)	4 (15.4)
Smoking status, cigarettes/d, n (%)			
0	4637 (92.1)	100 (90.9)	24 (92.3)
<10	107 (2.1)	4 (3.6)	0 (0)
10–20	245 (4.9)	4 (3.6)	1 (3.8)
>20	45 (0.9)	2 (1.8)	1 (3.8)
Medical history, n (%)			
Chronic hypertension	48 (1)	10 (9.1) ^a	4 (15.4) ^b
Diabetes mellitus	88 (1.7)	7 (6.4) ^a	0 (0)
Renal disease	6 (0.1)	0	3 (11.5) ^{b,c}
Autoimmune disease	68 (1.4)	4 (3.6)	1 (3.8)
Coagulation disorders	40 (0.8)	4 (3.6) ^a	0 (0)
Obstetric history, n (%)			
Nulliparous	2971 (59)	70 (63.6)	14 (53.8)
Previous PE	28 (0.6)	10 (9.1) ^a	5 (19.2) ^b
Previous IUGR ^d	28 (0.6)	1 (0.9)	3 (11.5) ^{b,c}
Mean BP, mmHg, median (IQR)	78.5 (74.1–83.1)	79.4 (74.9–84.1)	85.7 (80–89.7) ^{b,c}
Mean Uta-PI, median (IQR)	1.67 (0.53–1.25)	1.68 (1.54–1.84)	2.23 (1.75–3) ^{b,c}
Maternal serum biochemistry (MoM), median (IQR)			
PAPP-A	1.06 (0.53–1.25)	0.55 (0.28–1.05) ^a	0.87 (0.44–1.24)
β-HCG	1 (0.63–1.16)	0.96 (0.55–1.15)	0.92 (0.5–1.04)

BMI, body mass index; BP, blood pressure; HCG, human chorionic gonadotropin; IQR, interquartile range; IUGR, intrauterine growth restriction; MoM, multiple of expected normal median; PAPP-A, pregnancy-associated plasma protein-A; PE, preeclampsia; PI, pulsatility indices; Uta, uterine artery.

^a Significant comparison between unaffected and late PE; ^b Significant comparison between unaffected and early PE; ^c Significant comparison between late and early PE; ^d Birthweight <10th centile that required delivery <37 wk.

Scazzocchio. First-trimester preeclampsia screening in routine care. *Am J Obstet Gynecol* 2013.

MATERIALS AND METHODS**Subjects**

In this study, a prospective cohort composed of singleton pregnancies underwent routine first-trimester screening at the Department of Maternal-Fetal Medicine at Hospital Clinic Barcelona. The local ethics committee approved the study protocol and each patient provided written informed consent. Gestational age in all pregnancies was calculated based on the crown-rump length

(CRL) at first-trimester ultrasound.¹⁹ Maternal characteristics and medical history was recorded and BP, Uta Doppler and plasmatic concentrations of PAPP-A, and fβ-HCG were measured in the first trimester.

From May 2009 through October 2011, a total of 5759 women underwent examination. Of these participants, a total of 589 (10.2%) were excluded for the following reasons (nonexclusively): missing outcome data (n = 525), major

fetal defects or chromosomopathies (n = 25), miscarriage or fetal death <24 weeks (n = 80), and termination of pregnancy in the absence of medical indication (n = 21). After these participants were excluded, 5170 cases remained.

Predictive variables

Maternal characteristics and medical history were prospectively recorded at the time of first-trimester ultrasound (11.0–13.6 weeks) via a patient question-

naire. Characteristics recorded were: medical and obstetric history, maternal age, ethnicity, smoking status, parity, height, and weight.

A nurse measured BP automatically with a calibrated device (M6 Comfort; Omron Corp, Kyoto, Japan) in our outpatient clinics according to standard procedure. BP was measured in 1 arm (right or left) without distinction while women were seated and after a 5-minute rest. Mean arterial pressure (MAP) was calculated as: diastolic BP + (systolic – diastolic)/3.

UtA evaluation was performed transvaginally during the first-trimester ultrasound, as previously described.²⁰ Both UtA-pulsatility indices (PI) were automatically measured and mean UtA-PI was calculated.

Maternal serum PAPP-A and f β -HCG were measured using the DELFIA Xpress analyzer (Perkin-Elmer, Turku, Finland) between 8-12 weeks of gestation. Thereafter, these levels were converted to multiples of the expected normal median (MoM), which were corrected for CRL, maternal age, body mass index (BMI), smoking and diabetes status, and ethnicity according to local references.²¹

Outcome measures

PE was defined as systolic BP \geq 140 mm Hg and/or diastolic BP \geq 90 mm Hg on at least 2 occasions 4 hours apart, developing $>$ 20 weeks of gestation in previously normotensive women, and proteinuria $>$ 300 mg in a 24-hour urine specimen.²² Early PE was defined as PE requiring delivery $<$ 34 weeks. Doctors who made the diagnosis were blinded to the study parameters obtained during the first trimester.

Statistical analysis

The Mann-Whitney *U* test and Pearson χ^2 test were performed to make univariate comparisons of quantitative and qualitative variables, respectively, between groups. A post hoc Bonferroni correction was conducted to maintain a type I error of 0.05 ($P = .025$).

Logarithmic transformation was performed to normalize mean UtA-PI and MAP. In 52 cases, (1%) mean UtA-PI

could not be calculated and these values were replaced by the average value of the whole cohort. Expected log values were calculated for all cases using a linear regression analysis of unaffected cases and included the following covariables: maternal age at first-trimester ultrasound (years), CRL at first-trimester ultrasound (millimeters), maternal height (centimeters) and weight (kilograms) at examination, parity (nulliparous vs multiparous), smoking status upon examination (0, 1-9, 10-19, and \geq 20 cigarettes/d), and ethnicity (white European, South American, black, and other). Each individual observed value was expressed as a MoM of the expected value.

Logistic regression was used to estimate each woman's a priori risk with respect to the following covariates: medical history of diabetes; chronic hypertension; renal or autoimmune diseases; congenital and acquired thrombophilic conditions; obstetric history of PE or intrauterine growth restriction; maternal age; BMI (kg/m^2); smoking (cigarettes/d); and ethnicity and parity.

Logistic regression analysis was performed to estimate the individual risks for early and late PE with respect to the following covariables: a priori risk (log transformed), log MoM mean UtA-PI, log MoM MAP, log MoM PAPP-A, and log MoM f β -HCG.²¹ Receiver operating characteristic curves were performed to analyze model performance, which was expressed as DR for different cutoffs of false-positive rates (FPRs).


In all regression models, stepwise forward algorithms were performed to select variables at a *P* value cutoff of .05. Goodness-of-fit models were assessed by calculating Nagelkerke R^2 .

The statistical package SPSS 18.0 (IBM Corp, Armonk, NY) was used to conduct all the statistical analyses and graphs were generated with MedCalc (MedCalc Software, Mariakerke, Belgium).

RESULTS

Among the 5170 women included in the study, 136 (2.6%) developed PE, including 110 (2.1%) cases of late PE and 26 (0.5%) cases of early PE. Table 1 shows the epidemiological and clinical charac-

FIGURE 1
Box plots of log MoM of predictive variables among study groups



A, Mean uterine artery (UtA) Doppler pulsatility indices (PI); B, Mean arterial pressure (MAP); and C, pregnancy-associated plasma protein-A (PAPP-A) levels.

MoM, multiple of expected normal median; mUtA-PI, mean uterine artery-pulsatility indices; PE, preeclampsia.

Scazzocchio. First-trimester preeclampsia screening in routine care. *Am J Obstet Gynecol* 2013.

teristics of the population by study group.

Scatterplots showing mean UtA-PI and MAP (in log MoM values) against gestational age at delivery and the correlation between UtA-PI and MAP are provided in the Supplemental Figures in the Appendix.

The following formula best fit the expected log mean UtA-PI: $0.668018 - (0.002772 * \text{CRL}) - (0.001536 * \text{height}) - (0.001151 * \text{maternal age})$; $R^2 = 4.6\%$.

The following formula best fit the expected log MAP: $1.803485 + (0.002990 * \text{BMI}) + (0.000645 * \text{maternal age}) - (0.00421 \text{ if South American})$; $R^2 = 13.1\%$.

Figure 1 shows the distribution in log MoM of mean UtA-PI, MAP, and PAPP-A among the different study groups. The log MoM mean UtA-PI was significantly greater in the early PE group compared to unaffected ($P < .001$) and late PE ($P = .001$) groups. Similarly, log MoM MAP was significantly higher in the early PE group than in the unaffected ($P = .001$) and late PE ($P < .001$) groups. Log MoM PAPP-A was significantly lower in the late PE group compared to the unaffected group ($P < .001$).

The following model best fit the a priori risk for late and early PE [a priori risk = $e^y/(1 + e^y)$]:

Late PE $Y = -6.135 + (2.124 \text{ if previous PE}) + (1.571 \text{ if chronic hypertension}) + (0.958 \text{ if diabetes mellitus}) + (1.416 \text{ if thrombophilic condition}) - (0.487 \text{ if multipara}) + (0.093 * \text{BMI})$; $R^2 = 7.9\%$.

Early PE $Y = -7.703 + (0.086 * \text{BMI}) + (1.708 \text{ if chronic hypertension}) + (4.033 \text{ if renal disease}) + (1.931 \text{ if parous, previous PE}) + (0.005 \text{ if parous, no previous PE})$; $R^2 = 13\%$.

The following models best fit the patient-specific a posteriori risk (a posteriori risk = $e^y/[1 + e^y]$):

Late PE $Y = 0.328 + (2.205 * \log \text{ a priori risk}) - (1.307 * \log \text{ MoM PAPP-A})$; $R^2 = 10.1\%$

Early PE $Y = -0.320 + (2.681 * \log \text{ a priori risk}) + (13.132 * \log \text{ MoM$

mean UtA-PI) + (25.733 * log MoM MAP); $R^2 = 36.8\%$.

One example of the application of these models is a 35-year-old woman with a prothrombin gene mutation, but no other medical conditions, who underwent her first pregnancy. At the time of the first-trimester ultrasound (CRL, 65 mm), her height was 165 cm and weight was 65 kg (BMI 23.8 kg/m²). She had a mean UtA-PI of 1.85, a MAP of 90 mm Hg, and a PAPP-A of 0.87 MoM.

The expected log mean UtA-PI is: $0.668018 - (0.002772 * 65) - (0.001536 * 165) - (0.001151 * 35) = 0.194$.

The log MoM mean UtA-PI is: $\log(1.85) - 0.194 = 0.073$.

The expected log MAP is: $1.803485 + (0.00299 * 23.8) + (0.000645 * 35) = 1.897$.

The log MoM MAP is: $\log(90) - 1.897 = 0.057$.

The a priori odds for early PE is: $Y = -7.703 + (0.086 * 23.8) = -5.656$.

The a priori risk = $e^{-5.656}/(1 + e^{-5.656}) = 0.0034$

The a posteriori odds for early PE is: $Y = -0.320 + (2.681 * \log(0.0034)) + (13.132 * 0.073) + (25.733 * 0.057) = -4.4945$.

The a posteriori risk = $e^{-4.4945}/(1 + e^{-4.4945}) = 0.011 = 1/91$.

The same woman with a mean UtA-PI of 2.5 would have a risk of 1/18 for early PE.

Figure 2 shows the receiver operating characteristic curve for late PE (area under the curve, 0.710; 95% confidence interval, 0.658–0.763) and early PE (area under the curve, 0.96; 95% confidence interval, 0.94–0.98) models. The diagnostic performance for late and early PE for FPRs of 5%, 10%, and 15% is presented in Table 2. Table 3 shows the DR for early PE for a 5% and 10% FPR of each individual predictor and their combinations.


COMMENT

This study supports previous evidence that integrated first-trimester screening shows a high performance for the detection of early PE. The study evaluated a large sample of patients under typical clinical conditions and suggests that PE

screening can be satisfactorily performed in a routine care setting. In addition, screening was performed on European Mediterranean patients, normally associated with lower cardiovascular risks.¹⁸ The a priori risks for PE previously reported had been modeled using patient cohorts from the United Kingdom, with higher proportions of patients with cardiovascular risk factors and Afro-Caribbean origin.^{12,23} As previously shown, the maternal risk factors for PE may vary considerably in other populations,²⁴ which highlights the need to calculate a priori risks in each individual population. The results of this study support that screening for PE is effective even in populations with lower maternal a priori risk.

Early PE is the less prevalent form of the disease, but is a major contributor to maternal and perinatal complications in developed countries.⁸ The results of this study demonstrate that a combination of maternal history, BP, and ultrasound data in the first trimester achieves a reasonably high sensitivity, with DR of between 69% and 81% for 5% and 10% FPRs, respectively. These figures are slightly lower than those reported by Poon et al²⁵ (89.2% DR) in the Fetal Medicine Foundation (FMF) cohort using the same set of predictors. The most obvious difference between the studies performed by the FMF and this one is the performance of the maternal a priori risk. Thus, in our study the DR achieved by maternal factors was 31% for a 10% FPR. This figure is remarkably lower than the 41% obtained in the largest reported study, which was performed in the United Kingdom in 30,784 unselected low-risk women.²³ This higher performance is likely to be explained by differences in the prevalence of risk factors, including mean BMI and the proportions of black women and of patients with a previous PE, which were higher in the United Kingdom study. Aside from differences in a priori risk, it could be argued that some maternal predictors may have been recorded more accurately in previous studies performed in a research setting. Particularly, BP in previous studies reported by the FMF was measured following a strict protocol, in-

FIGURE 2
Receiver operator characteristic curves



Late (thin line) and early (thick line) preeclampsia.
Scazzocchio. First-trimester preeclampsia screening in routine care. Am J Obstet Gynecol 2013.

TABLE 3
Detection rate for early preeclampsia of each individual predictor and their combinations

Variable	5% FPR	10% FPR
A priori risk	25%	31.4%
MAP	38.5%	61.5%
Mean UtA-PI	46.2%	57.7%
A priori risk + MAP	46.3%	69.2%
A priori risk + mean UtA-PI	65%	73.3%

FPR, false-positive rate; MAP, mean arterial pressure; PI, pulsatility indices; UtA, uterine artery.
Scazzocchio. First-trimester preeclampsia screening in routine care. Am J Obstet Gynecol 2013.

UtA Doppler was the strongest predictor of early PE in this study. It improved the DR achieved by maternal factors from 31% to 73%. This is in line with previous studies. In a study performed by the FMF Poon et al¹³ reported that the addition of UtA measurements to maternal factors improved the DR from 37% to 65%, a slightly lower figure than that found in the present study. We speculate that the opportunity for improvement may be greater when the DR achieved by maternal factors is smaller. Important information provided by the current study is that the performance of UtA Doppler seems to be high regardless of the method of measurement. Poon et al,¹³ and in general all studies reported by the FMF, evaluated the UtA by trans-abdominal ultrasound while we predominantly used a vaginal approach. Additionally, the authors reported that the best DR was obtained using the lowest PI of any UtA, while the highest predictive value in our study was achieved using the mean PI of both arteries.¹³

This study evaluated 2 biochemical markers now used for the screening of Down syndrome. As expected, β HCG was not associated with an increased risk of PE. The findings concerning PAPP-A may seem more surprising, since previous studies had suggested an association between this biomarker and the subsequent risk of PE. However, the association of PAPP-A with PE is weak and it becomes nonsignificant when combined with other markers. Thus, the FMF,¹⁰ in

cluding >1 measurement in both arms, and recording as final an average of these measurements. While this protocol is optimal for measuring BP,²⁶ it is not current practice in most clinical settings. In the present study, BP was measured once in 1 arm following routine protocols by

health care staff serving at pregnancy clinics, and recorded in the patient's medical record. In any event, the DR achieved by combining maternal factors and BP in this study (46%) was remarkably similar to that reported by the FMF (48.6%) with the use of strict recording protocols.²⁵

TABLE 2
Diagnostic performance for late and early preeclampsia

Variable	Risk cutoff	Prevalence of positives %	DR, %	FPR, %	+LHR	-LHR
Late PE	>1/14	5.5	29.4	5	5.88	0.74
	>1/18	10.6	39.6	10	3.96	0.67
	>1/22	15.6	42.2	15	2.81	0.68
Early PE	>1/73	5.1	69.2	5	13.84	0.32
	>1/178	10.1	80.8	10	8.08	0.21
	>1/278	15.1	96.2	15	6.41	0.04

DR, detection rate; FPR, false-positive rate; LHR, likelihood ratio; PE, preeclampsia.
Scazzocchio. First-trimester preeclampsia screening in routine care. Am J Obstet Gynecol 2013.

a nested case-control study published in 2010 and including 90 PE and 180 unaffected controls, in which various combinations of maternal factors, soluble endoglin, placental growth factor, and PAPP-A were explored, concluded that PAPP-A did not contribute to the prediction of PE. In another study from the same group Akolekar et al²⁷ explored a combination of maternal factors, UtA-PI, inhibin A, and PAPP-A and reached similar conclusions, that is, PAPP-A did not improve prediction. Finally, and also from the FMF, Poon et al⁹ reported a study addressing the differential contribution of several factors to the prediction of PE, and concluded that PAPP-A added virtually no value to the prediction of PE when used in combination with UtA Doppler. We acknowledge that a potentially additional reason influencing the performance of PAPP-A is that 70% of the cases in this present study were measured at 8-10 weeks. It is biologically plausible that the predictive value for biochemical markers is later in the first trimester. Recent data concerning the longitudinal trends of several biochemical markers demonstrate that they correlate with UtA Doppler only late in the first trimester.²⁸ This may generate some conflict on designing combined strategies for the prediction of aneuploidy and PE. While the best performance for predicting trisomy 21 is achieved at 9-10 weeks, this might be detrimental to the prediction of PE. If the value of other biochemical markers such as angiogenic factors is confirmed in prospective large studies, an optimal trade-off between aneuploidy and PE screening should be determined.

The DR of late PE was much lower than that of early PE. The prevalence of late PE is significantly greater than that of early PE. While it remains a serious maternal-fetal health problem in developing countries, late PE is associated with normal perinatal outcomes in the vast majority of cases in the Western world and other developed countries. The development of late PE is thought to be significantly influenced by maternal predisposition with little or negligible placental component, which explains a much lower presence of the intrauterine growth

restriction that occurs in virtually all cases of early PE.²⁹ The low degree or absence of placental insufficiency, and the fact that maternal predisposition may occur due to a wide variety of subclinical conditions, makes predicting PE in the first trimester quite challenging. Consequently, the predictive value of screening at such early gestational age in previous studies has been consistently low.^{11-13,23,25}

This study was conducted in a large unselected population under usual clinical care conditions. This is a strength of the study and reinforces the notion that screening for PE is feasible and effective in populations with a lower a priori risk. Among the limitations of the study, we acknowledge that the performance of the screening here proposed should be validated in further prospective studies. In addition, while the personnel taking part in the study were indeed clinical staff, we acknowledge that, being a large tertiary center, the skills of the clinicians recording UtA Doppler, and consequently the reproducibility of the measurements, could have been higher than the average. Finally, the study did not evaluate any angiogenic factors, which currently have become strong candidates for the prediction of PE and have been shown to improve the performance of screening strategies.^{10,11} Assessment of placental growth factor in a future study in the same population is warranted.

To conclude, our study suggests that first-trimester screening combining maternal factors with UtA Doppler, BP, and PAPP-A is useful to predict PE in a routine care setting. Further studies evaluating the addition of other predictors are required. In addition, studies assessing the implementation of a screening strategy at first trimester to select women for prophylactic interventions are also needed. ■

REFERENCES

1. Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* 2009;33:130-7.
2. Tang LC, Kwok AC, Wong AY, Lee YY, Sun KO, So AP. Critical care in obstetrical patients: an eight-year review. *Chin Med J (Engl)* 1997;110:936-41.

3. Lewis G, ed. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving mothers' lives: reviewing maternal deaths to make motherhood safer—2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. London: CEMACH, 2007.
4. Gardosi J, Kady SM, McGeown P, Francis A, Tonks A. Classification of stillbirth by relevant condition at death (ReCoDe): population-based cohort study. *BMJ* 2005;331:1113-7.
5. Iams JD, Goldenberg RL, Mercer BM, et al. The preterm prediction study: recurrence risk of spontaneous preterm birth; National Institute of Child Health and Human Development maternal-fetal medicine units network. *Am J Obstet Gynecol* 1998;178:1035-40.
6. Cuckle HS. Screening for pre-eclampsia—lessons from aneuploidy screening. *Placenta* 2011;32(Suppl):S42-8.
7. Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguere Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. *J Obstet Gynaecol Can* 2009;31:818-26.
8. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. *Obstet Gynecol* 2001;97:533-8.
9. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. *Ultrasound Obstet Gynecol* 2009;33:23-33.
10. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. *Ultrasound Obstet Gynecol* 2010;35:680-7.
11. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. *Hypertension* 2009;53:812-8.
12. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. *J Hum Hypertens* 2010;24:104-10.
13. Poon LC, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks. *Ultrasound Obstet Gynecol* 2009;34:142-8.
14. Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH. Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11-13 weeks. *Hypertens Pregnancy* 2010;30:93-107.
15. Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. *Prenat Diagn* 2010;30:216-23.
16. Odibo AO, Zhong Y, Goetzinger KR, et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal character-

istics in the prediction of pre-eclampsia. *Placenta* 2011;32:598-602.

17. Pilalis A, Souka AP, Antsaklis P, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation. *Ultrasound Obstet Gynecol* 2007;29:135-40.

18. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations; monitoring trends and determinants in cardiovascular disease. *Lancet* 1999;353:1547-57.

19. Robinson HP, Sweet EM, Adam AH. The accuracy of radiological estimates of gestational age using early fetal crown-rump length measurements by ultrasound as a basis for comparison. *Br J Obstet Gynaecol* 1979;86:525-8.

20. Gomez O, Martinez JM, Figueras F, et al. Uterine artery Doppler at 11-14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. *Ultrasound Obstet Gynecol* 2005;26:490-4.

21. Casals E, Aibar C, Martinez JM, et al. First-trimester biochemical markers for Down syndrome. *Prenat Diagn* 1999;19:8-11.

22. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). *Hypertens Pregnancy* 2001;20:IX-XIV.

23. Yu CK, Smith GC, Papageorgiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of pre-eclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. *Am J Obstet Gynecol* 2006;195:330.

24. Shamsi U, Hatcher J, Shamsi A, Zuberi N, Qadri Z, Saleem S. A multicenter matched case control study of risk factors for preeclampsia in healthy women in Pakistan. *BMC Womens Health* 2010;10:14.

25. Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. *Ultrasound Obstet Gynecol* 2009;34:497-502.

26. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals, part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. *Hypertension* 2005;45:142-61.

27. Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. *Prenat Diagn* 2009;29:753-60.


28. Wortelboer EJ, Koster MP, Kuc S, et al. Longitudinal trends in fetoplacental biochemical markers, uterine artery Doppler flow velocities and maternal blood pressure during the first-trimester of pregnancy. *Ultrasound Obstet Gynecol* 2011;38:383-8.

29. Crispi F, Dominguez C, Llubra E, Martin-Gallan P, Cabero L, Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. *Am J Obstet Gynecol* 2006;195:201-7.

APPENDIX

SUPPLEMENTAL FIGURE 1

Mean uterine artery PI (in log MoM values) against GA at delivery




Blue dots = unaffected; Black squares = affected by preeclampsia.

GA, gestational age; MoM, multiple of expected normal median; PI, pulsatility indices.

Scazzocchio. First-trimester preeclampsia screening in routine care. *Am J Obstet Gynecol* 2013.

SUPPLEMENTAL FIGURE 2

MAP (in log MoM values) against GA at delivery




Blue dots = unaffected; Black squares = affected by preeclampsia.

GA, gestational age; MAP, mean arterial pressure; MoM, multiple of expected normal median.

Scazzocchio. First-trimester preeclampsia screening in routine care. *Am J Obstet Gynecol* 2013.

SUPPLEMENTAL FIGURE 3

Correlation between uterine artery PI and MAP (in log MoM)

Blue dots = unaffected; Black squares = affected by preeclampsia.

MAP, mean arterial pressure; MoM, multiple of expected normal median; PI, pulsatility indices.

Scazzocchio. First-trimester preeclampsia screening in routine care. *Am J Obstet Gynecol* 2013.